Aim of this study was to investigate if cellular [F]FBPA uptake can be increased upon preloading with amino acids. [F]FBPA uptake was assessed in HuH-7, CaCo-2 and B16-F1 cells pretreated with different concentrations or incubation times of L-BPA, L-tyrosine or L-DOPA. Without preloading, highest uptake of [F]FBPA was observed in B16-F1 cells, followed by CaCo-2 cells and HuH-7 cells. In all cell lines higher [F]FBPA accumulation (up to 1.65-fold) was obtained with increasing L-BPA, L-DOPA and L-tyrosine concentrations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apradiso.2016.08.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of D-isomers of 4-borono-2-F-fluoro-phenylalanine and O-C-methyl-tyrosine as brain tumor imaging agents: a comparative PET study with their L-isomers in rat brain glioma.
EJNMMI Res
June 2018
Central Research Laboratory, Hamamatsu Photonics K.K., 5000 Hirakuchi, Hamakita, Hamamatsu, Shizuoka, 434-8601, Japan.
Background: The potential of the D-isomerization of 4-borono-2-F-fluoro-phenylalanine (F-FBPA) to improve its target tumor to non-target normal brain tissue ratio (TBR) was evaluated in rat brain glioma and compared with those of L- and D-C-methyl-tyrosine (C-CMT). The L- or D-isomer of F-FBPA was injected into rats through the tail vein, and their whole body kinetics and distributions were assessed using the tissue dissection method up to 90 min after the injection. The kinetics of L- and D-F-FBPA or L- and D-C-CMT in the C-6 glioma-inoculated rat brain were measured for 90 or 60 min, respectively, using high-resolution animal PET, and their TBRs were assessed.
View Article and Find Full Text PDFOn the applicability of [F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy.
Nucl Med Biol
January 2017
Health and Environment Department, AIT Austrian Institute of Technology GmbH, 2444, Seibersdorf, Austria. Electronic address:
Introduction: In recent years extra-corporal application of boron neutron capture therapy (BNCT) was evaluated for liver primary tumors or liver metastases. A prerequisite for such a high-risk procedure is proof of preferential delivery and high uptake of a B-pharmaceutical in liver malignancies. In this work we evaluated in a preclinical tumor model if [F]FBPA tissue distribution measured with PET is able to predict the tissue distribution of [B]L-BPA.
View Article and Find Full Text PDFPreloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [F]FBPA in human and mouse tumour cell lines.
Appl Radiat Isot
December 2016
Biomedical Systems, Health & Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria. Electronic address:
Aim of this study was to investigate if cellular [F]FBPA uptake can be increased upon preloading with amino acids. [F]FBPA uptake was assessed in HuH-7, CaCo-2 and B16-F1 cells pretreated with different concentrations or incubation times of L-BPA, L-tyrosine or L-DOPA. Without preloading, highest uptake of [F]FBPA was observed in B16-F1 cells, followed by CaCo-2 cells and HuH-7 cells.
View Article and Find Full Text PDFClinical implementation of 4-dihydroxyborylphenylalanine synthesised by an asymmetric pathway.
Eur J Pharm Sci
February 2003
Department of Neurology, Helsinki University Central Hospital, PO Box 220, FIN-00029 HUS, Helsinki, Finland.
Boron neutron capture therapy (BNCT) is an experimental therapeutic modality combining a boron pharmaceutical with neutron irradiation. 4-Dihydroxyborylphenylalanine (L-BPA) synthesised via the asymmetric pathway by Malan and Morin [Synlett. 167-168 (1996)] was developed to be the boron containing pharmaceutical in the first series of Finnish BNCT clinical trials.
View Article and Find Full Text PDFMelanogenesis investigation leading to selective melanoma neutron capture therapy and diagnosis.
J Dermatol
November 1994
Mishima Institute for Dermatological Research, Kobe Kaisei Hospital, Japan.
Basic investigation into the nature of melanin monomer and polymer synthesis in pigment cells has revealed many of the new underlying factors involved in its regulation and control by three melanogenesis-related genes, tyrosinase, TRP-1 and TRP-2, and other non-tyrosinase glycoproteins. Pigment cells can undergo clinically and biologically recognizable progressive multi-step carcinogenesis. Generally parallel to this progressive cancerization is accentuated melanogenesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!